One Dose versus Three Doses of Benzathine Penicillin G in Early Syphilis in People Living with HIV: A Systematic Review and Meta-Analysis.

Authors

Martin Cevallos-Cueva, Sümeyye Aktaş, Luiza Fenalte Streher, Ana Clara Felix De Farias Santos, Lorena Oliveira Fonseca, Ayşe Deniz Gökengin, Henry J C De Vries

Published in

Sexually transmitted diseases. Oct 16, 2026. Epub Oct 16, 2026.

Abstract

Despite the current recommendations of the CDC and IUSTI, controversy persists regarding the adequate dose and duration of benzathine penicillin G (BPG) for early syphilis in people living with HIV (PLWH). PubMed, Embase, and Cochrane were searched from inception to October 2025 for studies comparing a single-dose versus a 3-dose BPG regimen in PLWH with early syphilis. A random-effects meta-analysis was performed using risk ratios (RRs) with 95% confidence intervals (CIs). The primary outcome included serologic cure, defined as a ≥4-fold (2-dilution) decline from baseline in antibody titers measured by nontreponemal (lipoidal antigen) tests, including rapid plasma reagin (RPR) or venereal disease research laboratory (VDRL) tests, at 6 and 12 months. A total of 8 studies, including 2randomized controlled trials (RCTs) and 6observational studies, were included. Pooled analysis showed no significant difference in serologic cure between a single-dose versus 3-dose BPG at 6months (RR 1.00; 95% CI 0.93 to 1.07; P = 0.95) or 12 months (RR 0.98; 95% CI 0.92 to 1.04; P = 0.46). Overall, our pooled results did not show a significant difference between single-dose and 3-dose BPG. However, our study did not evaluate selected high-risk subgroups, particularly individuals with advanced immunosuppression or untreated HIV infection. Thus, a potential benefit of enhanced therapy in these specific populations cannot be entirely ruled out, underscoring the need for future RCTs focused on these subgroups and designed to stratify or adjust for key disease-modifying factors.

PMID:
42886493
Bibliographic data and abstract were imported from PubMed on 17 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.